A Monitoring System Based on the Multifactorial Dynamic Perfusion Index to Predict and Prevent the Onset of Postoperative Acute Kidney Injury After Cardiac Surgery, Based on a Dynamic Collection of Hemodynamic and Clinical Parameters During Cardiopulmonary Bypass

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorIRCCS Policlinico S. Donato

About this trial

This project is based on a predictive alghorithm (Multifactorial Dynamic Perfusion Index-MDPI) already published and covered by a patent. The MDPI is based on a dynamic collection of 7 different variables during cardiopulmonary bypass (CPB) and provides a probability index for postoperative acute kidney injury. The study design is a multicenter observational prospective trial developed through 3 work packages, addressing (1) external validation of the MDPI in a series of 800 adult cardiac surgery patients collected in 2 Institutions (2) development of a novel MDPI to be applied in infants \< 20 kg undergoing cardiac surgery (200 patients) and (3) verification of of other possible outcomes that may be predicted by the MDPI. Since many of the predictive variables are modifiable by the perfusionist/anesthesiologist during CPB, it is a tool that allows therapeutic manouvres. Ultimately, the MDPI will be incorporated in a dedicated monitor to provide an on-line "flight control" during CPB. Work package 1 will be performed at Units 1 and 2; the parameters composing the MDPI will be collected using the existing CPB monitors that routinely measure the hematocrit, the oxygen delivery, the time of exposure to a pre-defined critical oxygen delivery, the mean arterial pressure, and the CPB duration. Blood lactates and transfusions will be manually inputed. The MDPI will be calculated off-line and tested for association and predictivity (discrimination and calibration) with respect to postoperative AKI defined according to the K-DIGO classification. Workpackage 2 is dedicated to infants, with the purpose of developing an MDPI dedicated to low-weight infants (I-MDPI). This will be develop in Unit 1 that performs congenital heart surgery. The same variables of the MDPI will be collected, plus additional variables specific for infants (blood to prime the oxygenator, plasma for the same purpose; venous oxygen saturation, and others). The variables being independently associated with AKI will enter a logistic regression equation that will be the basis for the I-MDPI. Workpackage 3 considers that AKI is associated with a prolonged mechanical ventilation time, prolonged stay in the intensive care unit and in the hospital; and mortality. Therefore, the MDPI may be predictive of other postoperative complications, apart from AKI, and even of mortality. Some of the factors included in the MDPI may directly (low hematocrit) or indirectly (prolonged CPB duration, excessive hemodilution, low mean arterial pressure) affect the hemostatic system and/or trigger packed red cells transfusions. Additionally, CPB itself is a determinant of a coagulophatic state with associated postoperative bleeding which, in turns, increases the mortality. The specific aim 3 is to confirm the hypothesis that the MDPI may be predictive of one or more of this non-AKI postoperative complications and of 30-days mortality. In the same series of work package and aim 1, these complications will be collected and the MDPI tested for predictive ability of each one of these complications and 30-days mortality. At present, the MDPI can only be calculated off-line, and this greatly limits its applicability. The last step of the aim 3 is based on the involvement of software experts and partnership with companies interested in including the MDPI into their existing monitors; as such, the MDPI patent would be given under licence of the existing patent owned by the IRCCS Policlinico San Donato.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

patients undergoing cardiac surgery with cardiopulmonary bypass

patients >18 years for WP1 and WP3; patients <6 years and weight <20 kg for WP2

willingness to participate and sign the informed consent

Disqualifiers

chronic renal failure on dyalisis for WP1 and WP3

emergency surgery for all WP

refusal to partecipate

Trial population

Patients hospitalized in our Institution for a scheduled cardiac surgery with cardiopulmonary bypass

Trial design

Design model

Cohort

Time perspective

Prospective

Treatments tested in this trial

  • PEQUOD

    Other intervention

    During cardiopulmonary bypass registration of the parameters of interest by the Livanova BE-CAPTA monitor. After surgery, registration of creatinine values up to 48 postoperative hours.

Treatment groups

800 Participants
are divided into 1 treatment group
Group A: PEQUOD1 intervention

Trial outcomes

Primary outcomes

1

Number of patients with postoperative acute kidney injury

Occurence of any stage acute kidney injury as defined by the AKIN criteria for adults and KDIGO criteria for infants

Time frame
First 48 postoperative hours

Secondary outcomes

1

Number of patients with postoperative low cardiac output

Use of inotrope drugs for more than 48 hours and/or mechanical support

Time frame
First 48 postoperative hours
2

Number of patients experiencing postoperative major morbidity

As defined by STS criteria as one or more of the following items: AKI stage 2, stroke, mechanical ventilation duration \> 48 hours, sepsis, surgical re-exploration

Time frame
First 48 postoperative hours
3

Number of patients who needed prolonged ICU stay

ICU stay duration \> 4 days

Time frame
First 4 postoperative days
4

Number of deceased patients

Dead or alive status

Time frame
30 days after surgery

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.